3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

59.05 +0.74 ( +1.27% ) 4:02 5/24/19 Pricing delayed 20 minutes

Volume 157,213

Recent News

See All
May 20, 2019 ­Nevro Names D. Keith Grossman Chairman of the Board; Michael DeMane as Lead Director
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that its Board of Directors has elected D. Keith Grossman, the Company's President and CEO, to additionally serve as Chairman of the Board.  Mr. Grossman assumes the Chairmanship effective today, following the Company's Annual Meeting of Stockholders.  Michael DeMane, who served as Chairman of the Board since January of 2017, will serve as Lead Director. About Nevro Corp.  Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza II™ System are the only SCS systems...
May 9, 2019 Nevro Reports First Quarter 2019 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the first quarter ended March 31, 2019. Revenue for the first quarter of 2019 was $82.1 million, a 6% decrease compared to $87.6 million during the prior year period.  U.S. revenue for the first quarter of 2019 was $65.8 million, a 7% decrease compared to $70.6 million in the prior year period.  International revenue was $16.3 million compared to $17.0 million in the prior year period. This represents a 4% decrease on an as-reported basis and a 4% increase on a constant currency basis.  The year-over-year decrease in U.S. revenue was primarily due to the Company's decision in the first quarter of 2019 to diminish the impact of high volume product orders.  Absent this change, first quarter 2019 U.S. revenues would have been approximately in line with the prior year. "The Nevro team is intently focused on...
May 1, 2019 ­Nevro to Present at the Bank of America Merrill Lynch Healthcare Conference 2019
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the Company will be participating in the Bank of America Merrill Lynch Healthcare Conference 2019 in Las Vegas, NV. President and CEO Keith Grossman is scheduled to present on Tuesday, May 14, 2019 at 3:00 pm Pacific Time. A live webcast of the presentation, as well as an archived recording, will be available on the "Investors" section of the Company's website at www.nevro.com. About Nevro Corp.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza II™...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.